Literature DB >> 11403228

Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

G Valentini1, A Baroni, K Esposito, C Naclerio, E Buommino, A Farzati, G Cuomo, B Farzati.   

Abstract

Our objective was to investigate the phenotype of helper T cells in the peripheral blood of patients with systemic sclerosis (SSc). PBMC from 15 patients with SSc and 15 sex- and age-matched controls were investigated for lymphocyte subpopulations (CD3, CD4, CD8, CD19, CD16/CD56, CD3-DR); IL-2, IL-4, and IFN-gamma mRNAs; and the relative cytokines in their cytoplasm. The last assay was carried out both in unstimulated and in PMA-activated PBMC. SSc patients presented a higher percentage of activated T cells, CD3+ DR+ (19.7 +/- 9.9 vs 5.1 +/- 2.5%; P < 0.0001); 12 of them presented IFN-gamma mRNA-positive cells; and none IL-2 or IL-4 mRNAs. Under basal conditions, PBMC from six SSc patients contained IL-2, IL-4, and IFN-gamma (i.e., they showed both Th1 and Th2 activation), and 1 IFN-gamma only. PMA-stimulated PBMC of patients differed from those of controls only in the increased percentage of IFN-gamma positive cells (52 +/- 12 vs 37 +/- 11%; P < 0.01). Our study demonstrates that Thl activation occurs in the peripheral blood of SSc patients. This evidence must be faced with from both a pathogenetic and a therapeutical point of view.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403228     DOI: 10.1023/a:1011024313525

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  36 in total

1.  Natural killer activity and antibody-dependent cellular cytotoxicity in progressive systemic sclerosis.

Authors:  M Grazia Cifone; R Giacomelli; G Famularo; R Paolini; C Danese; T Napolitano; A Procopio; A M Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

Review 2.  The concept of type-1 and type-2 helper T cells and their cytokines in humans.

Authors:  G Del Prete
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

3.  Circulating levels of soluble CD30 are increased in patients with systemic sclerosis (SSc) and correlate with serological and clinical features of the disease.

Authors:  R Giacomelli; P Cipriani; R Lattanzio; M Di Franco; M Locanto; I Parzanese; A Passacantando; A Ciocci; G Tonietti
Journal:  Clin Exp Immunol       Date:  1997-04       Impact factor: 4.330

4.  Soluble interleukin-2 receptor, interleukin-2 and interleukin-4 in sera and supernatants from patients with progressive systemic sclerosis.

Authors:  G Famularo; A Procopio; R Giacomelli; C Danese; S Sacchetti; M A Perego; A Santoni; G Tonietti
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

5.  Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension.

Authors:  A Giunta; E Tirri; S Maione; S Cangianiello; A Mele; A De Luca; G Valentini
Journal:  Ann Rheum Dis       Date:  2000-02       Impact factor: 19.103

6.  Scleroderma renal crisis analysis of prevalence and outcome in a large italian series.

Authors:  G L Montagna; A Baruffo; L Maja; E Tirri; C Matrone; M Vatti; G Valentini
Journal:  J Clin Rheumatol       Date:  1997-08       Impact factor: 3.517

7.  Monocytes of patients wiht systemic sclerosis (scleroderma spontaneously release in vitro increased amounts of superoxide anion.

Authors:  P Sambo; L Jannino; M Candela; A Salvi; M Donini; S Dusi; M M Luchetti; A Gabrielli
Journal:  J Invest Dermatol       Date:  1999-01       Impact factor: 8.551

Review 8.  Hypothesis: decreased use of pediatric aspirin has contributed to the increasing prevalence of childhood asthma.

Authors:  A E Varner; W W Busse; R F Lemanske
Journal:  Ann Allergy Asthma Immunol       Date:  1998-10       Impact factor: 6.347

9.  Phenotype of peripheral blood lymphocytes in patients with progressive systemic sclerosis: activated T lymphocytes and the effect of D-penicillamine therapy.

Authors:  B Freundlich; S A Jimenez
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

10.  Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis.

Authors:  M Gruschwitz; N Sepp; H Kofler; G Wick
Journal:  Immunobiology       Date:  1991-06       Impact factor: 3.144

View more
  16 in total

1.  Mapping of the immunodominant T cell epitopes of the protein topoisomerase I.

Authors:  S Veeraraghavan; E A Renzoni; H Jeal; M Jones; J Hammer; A U Wells; C M Black; K I Welsh; R M du Bois
Journal:  Ann Rheum Dis       Date:  2004-08       Impact factor: 19.103

2.  A cell model system to study regulation of phosphotidylinositol 3-kinase and protein kinase B activity by cytokines/growth factors produced by type I collagen stimulated immune cells from patients with systemic sclerosis.

Authors:  Thomas M Chiang; Arnold E Postlethwaite
Journal:  Biochim Biophys Acta       Date:  2007-04-18

Review 3.  The role of the acquired immune response in systemic sclerosis.

Authors:  Carlo Chizzolini; Francesco Boin
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

4.  CD8+ T cells in systemic sclerosis.

Authors:  Patrizia Fuschiotti
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

5.  T cell polarization identifies distinct clinical phenotypes in scleroderma lung disease.

Authors:  Francesco Boin; Umberto De Fanis; Susan J Bartlett; Fredrick M Wigley; Antony Rosen; Vincenzo Casolaro
Journal:  Arthritis Rheum       Date:  2008-04

6.  Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles.

Authors:  Kathryn S Torok; Katherine Kurzinski; Christina Kelsey; Jonathan Yabes; Kelsey Magee; Abbe N Vallejo; Thomas Medsger; Carol A Feghali-Bostwick
Journal:  Semin Arthritis Rheum       Date:  2015-06-17       Impact factor: 5.532

7.  CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma.

Authors:  Ayumi Yoshizaki; Yohei Iwata; Kazuhiro Komura; Fumihide Ogawa; Toshihide Hara; Eiji Muroi; Motoi Takenaka; Kazuhiro Shimizu; Minoru Hasegawa; Manabu Fujimoto; Thomas F Tedder; Shinichi Sato
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

8.  Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement.

Authors:  E Scala; S Pallotta; A Frezzolini; D Abeni; C Barbieri; F Sampogna; O De Pità; P Puddu; R Paganelli; G Russo
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

Review 9.  Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited.

Authors:  Armando Gabrielli; Silvia Svegliati; Gianluca Moroncini; Giovanni Pomponio; Mariarosaria Santillo; Enrico V Avvedimento
Journal:  Semin Immunopathol       Date:  2008-06-12       Impact factor: 11.759

10.  Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations.

Authors:  Pravitt Gourh; Frank C Arnett; Shervin Assassi; Filemon K Tan; Mei Huang; Laura Diekman; Maureen D Mayes; John D Reveille; Sandeep K Agarwal
Journal:  Arthritis Res Ther       Date:  2009-10-02       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.